Jamal El Mosleh

Chief Executive Officer

Finansinspektionen (Sweden) Files from Sweden

Compiled from cited public records — every figure names the disclosure it came from, none copied from any wealth ranking. How we calculate this.

Positions on file
1
positions reconstructed from transactions reported to Finansinspektionen (FI) in Sweden

Not measurable for this profile: Reconstructed positions · 1-day change

Trading activity Mar 19, 2018 – May 27, 2025

Jamal El Mosleh reported 23 transactions between Mar 19, 2018 and May 27, 2025. The buy and sell totals below count only codes SACQ, SDIS.

Open-market buys (SACQ)
5.41M SEK
10 purchases on file priced rows only
Open-market sales (SDIS)
5.92M SEK
7 sales on file priced rows only
All reported transactions
23
every code, including awards and exercises
Pattern
No transaction in the final 12 months of the window
last 12 months of the window

Events from filings

Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.

8 insiders bought Elicera Therapeutics AB shares worth 570,141 SEK on Jul 5, 2021

Cluster buying

8 different insiders made 8 open-market purchases of this company’s shares within a short window. Each row below is one reported trade. At least one price in this event could not be cross-checked against other trades in the same security, so read the total with extra care.

8 insiders bought Elicera Therapeutics AB shares worth 570,141 SEK on Jul 5, 2021
Date Insider Transaction Shares Price Value Filing
Jul 5, 2021 Magnus Essand SACQ Acquisition 12,100 4.30 SEK 52,030 SEK FI filing ↗
Jul 5, 2021 Agneta Edberg SACQ Acquisition 12,791 4.30 SEK 55,001 SEK FI filing ↗
Jul 5, 2021 Karin helene Hoogendoorn SACQ Acquisition 23,000 4.30 SEK 98,900 SEK FI filing ↗
Jul 5, 2021 Jan Zetterberg SACQ Acquisition 14,000 4.30 SEK 60,200 SEK FI filing ↗
Jul 5, 2021 Jamal El Mosleh SACQ Acquisition 23,000 4.30 SEK 98,900 SEK FI filing ↗
Jul 5, 2021 Di Yu SACQ Acquisition 12,100 4.30 SEK 52,030 SEK FI filing ↗
Jul 5, 2021 Margareth Jorvid SACQ Acquisition 12,100 4.30 SEK 52,030 SEK FI filing ↗
Jul 5, 2021 Rolf Ingvar Lennart Karlsson SACQ Acquisition 23,500 4.30 SEK 101,050 SEK FI filing ↗

Total of the rows above: 570,141 SEK, in the currency the filings report.

Source: Finansinspektionen (Sweden); every row links to where it was published. Event computed Sep 14, 2026.

Reported transactions

Price 0.00 is a real reported figure on allotments, gifts and option exercises — not a missing number. The 23 most recent rows are grouped into 22 lines by date, company and transaction type — open a line to see every lot with its own source link.

How to read this list

Every row is one insider transaction as reported to FI, with a link back to the FI register filtered to that issuer and publication date. FI publishes no per-report permalink, so the link is a search, not a document. Where the record carries no price at all we leave the cell empty instead of guessing one.

The shares and money on a grouped line add up only the lots listed inside that line, and only when every one of them carries the figure. Where a group mixes more than one reporting currency we leave the money blank rather than convert — no source publishes the rate that conversion would need.

  1. Elicera Therapeutics AB SDIS Disposal 20,000 shares 131.8K SEK at 6.59 SEK FI filing ↗
  2. Elicera Therapeutics AB SDIS Disposal 25,000 shares 176.5K SEK at 7.06 SEK FI filing ↗
  3. Elicera Therapeutics AB SDIS Disposal 102,500 shares 667.3K SEK at 6.51 SEK FI filing ↗
  4. Elicera Therapeutics AB SDIS Disposal 237,500 shares 1.50M SEK at 6.30 SEK FI filing ↗
  5. Elicera Therapeutics AB SSUB Subscriptionnot a buy/sell decision 151,900 shares 281.0K SEK at 1.85 SEK FI filing ↗
  6. Elicera Therapeutics AB SACQ Acquisition 50,000 shares 50.0K SEK at 1.00 SEK FI filing ↗
  7. Elicera Therapeutics AB SACQ Acquisition 2,687,000 shares 3.44M SEK at 1.28 SEK FI filing ↗
  8. Elicera Therapeutics AB SDIS Disposal 2,687,000 shares 3.44M SEK at 1.28 SEK FI filing ↗
  9. Elicera Therapeutics AB SSUB Subscriptionnot a buy/sell decision 21,700 shares 351.5K SEK at 16.20 SEK FI filing ↗
  10. Elicera Therapeutics AB SDIS Disposal 1,687,000 shares 2.7K SEK at 0.00 SEK FI filing ↗
  11. Elicera Therapeutics AB SACQ Acquisition 31,000 shares 158 SEK at 0.01 SEK FI filing ↗
  12. Elicera Therapeutics AB SDIS Disposal 500,000 shares 1.2K SEK at 0.00 SEK FI filing ↗
  13. Elicera Therapeutics AB SACQ Acquisition 64,500 shares 1.2K SEK at 0.02 SEK FI filing ↗
  14. Elicera Therapeutics AB SRLI Return of loan increasenot a buy/sell decisionreported at zero 2,583,333 shares 0 SEK at 0.00 SEK FI filing ↗
  15. Elicera Therapeutics AB SACQ Acquisition 23,000 shares 98.9K SEK at 4.30 SEK FI filing ↗
  16. Elicera Therapeutics AB SALL Allotment × 2not a buy/sell decision 26,000 shares 104.0K SEK
    The 2 lots that make up this line, each with the source behind it.
    Shares Price Value Filing
    13,000 0.00 SEKreported at zero 0 SEK FI filing ↗
    13,000 8.00 SEK 104.0K SEK FI filing ↗
  17. Elicera Therapeutics AB SLNG Loan grantednot a buy/sell decisionreported at zero 2,583,333 shares 0 SEK at 0.00 SEK FI filing ↗
  18. Annexin Pharmaceuticals AB (publ) SACQ Acquisition 38,452 shares 61.1K SEK at 1.59 SEK FI filing ↗
  19. Annexin Pharmaceuticals AB (publ) SACQ Acquisition 94,410 shares 830.8K SEK at 8.80 SEK FI filing ↗
  20. Annexin Pharmaceuticals AB (publ) SACQ Acquisition 94,410 shares 830.8K SEK at 8.80 SEK FI filing ↗
  21. Annexin Pharmaceuticals AB (publ) SACQ Acquisition 11,364 shares 100.0K SEK at 8.80 SEK FI filing ↗
  22. Annexin Pharmaceuticals AB (publ) SACQ Acquisitionreported at zero 11,364 shares 0 SEK at 0.00 SEK FI filing ↗

Reconstructed positions

Reconstructed by adding up every transaction this person reported to FI since 2016. FI publishes transactions, not balances, so this is a computed figure, not a disclosed one — and it omits anything held before the register began.

What is not counted here

Each row comes from a public disclosure named on this page. Private companies, real estate, bonds and crypto are not in those disclosures and are therefore not counted here. Shares held through a holding company are recorded against that company, not against the individual behind it.

Equity positions reported to Finansinspektionen (FI) in Sweden, with the disclosure date shown on each row.
Issuer ISIN Security Shares Price Value Form Reported Filing
Annexin Pharmaceuticals AB (publ) SE0009664154 ANNX 38,452 — — FI marknadssok.fi.se ↗

Other shareholders on record at the same companies

People who also appear on the shareholder record of a company where Jamal El Mosleh reports shares.

Sharing a filing does not mean they work together day to day — it means both names appear on the same issuer’s insider record.

Sources

Every figure on this page is quoted from the public record named beside it, with the date it was true. Nothing here is our own calculation.

Think a number here is wrong? Check the named disclosure and its date against the tables above — how to report it.

Profile record last refreshed Sep 14, 2026.